2023 ESMO | 盘点！ADC药物相关进展

LBA11 - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial.

针对经治的无法手术或转移性激素受体阳性、HER2阴性（HR+/HER2-）乳腺癌（BC）患者，Datopotamab deruxtecan（Dato-DXd）与化疗的比较研究：TROPION-Breast01随机III期试验的初步结果。

Presentation Number: LBA11

Speakers: Aditya Bardia (Boston, United States of America)

Lecture Time: 16:30 - 16:42

Session Name: Presidential 3 (ID 156)

Date: Mon, 23.10.2023

Session Type: Proffered Paper session

376O - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): UpDate:d survival results of the randomized, phase 3 DESTINY-Breast04 study.

德曲妥珠单抗（T-DXd）与医生选择疗法（TPC）治疗HER2低表达不可切除和/或转移性乳腺癌（mBC）患者（pts）：随机III期DESTINY-Breast04研究的最新生存结果。

Presentation Number: 376O

Speakers: Shanu Modi (New York, United States of America)

Lecture Time: 10:25 - 10:35

Session Name: Proffered Paper session - Breast cancer, metastatic (ID 40)

Date: Sat, 21.10.2023

Session Type: Proffered Paper session

377O - A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03.

DESTINY-Breast（DB）01研究、DB02和DB03研究中德曲妥珠单抗（T-DXd）对HER2阳性（HER2+）转移性乳腺癌（mBC）伴脑转移（BMs）患者（pts）疗效的汇总分析。

Presentation Number: 377O

Speakers: Sara A. Hurvitz (Santa Monica, United States of America)

Lecture Time: 10:55 - 11:05

Session Name: Proffered Paper session - Breast cancer, metastatic (ID 40)

Date: Sat, 21.10.2023

Session Type: Proffered Paper session

379MO - Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study.

Datopotamab deruxtecan (Dato-DXd) + 度伐利尤单抗 (D) 用于不可切除的局部晚期/转移性三阴性乳腺癌 (a/mTNBC) 的一线 (1L) 治疗：Ib/II期BEGONIA研究的最新结果。

Presentation Number: 379MO

Speakers: Peter Schmid (London, United Kingdom)

Lecture Time: 08:30 - 08:35

Session Name: Mini oral session - Breast cancer, metastatic (ID 77)

Date: Sun, 22.10.2023

Session Type: Mini Oral session

380MO - SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial

SKB264（MK-2870）用于经治的转移性激素受体阳性（HR+）和HER2阴性乳腺癌患者的I/II期单臂篮子试验。

Presentation Number: 380MO

Speakers: Yongmei Yin (Nanjing, China)

Lecture Time: 08:35 - 08:40

Session Name: Mini oral session - Breast cancer, metastatic (ID 77)

Date: Sun, 22.10.2023

Session Type: Mini Oral session

381O - First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors.

靶向B7-H4的ADC药物HS-20089，用于晚期实体瘤患者的首次人体试验/I期试验。

Presentation Number: 381O

Speakers: Jian Zhang (Shanghai, China)

Lecture Time: 10:15 - 10:25

Session Name: Proffered Paper session - Breast cancer, metastatic (ID 40)

Date: Sat, 21.10.2023

Session Type: Proffered Paper session

385MO - A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors.

一项DP303c用于经治HER2阳性晚期实体瘤患者的多中心、开放标签、剂量递增和扩展研究。

Presentation Number: 385MO

Speakers: Yiqun Du (Shanghai, China)

Lecture Time: 09:30 - 09:35

Session Name: Mini oral session - Breast cancer, metastatic (ID 77)

Date: Sun, 22.10.2023

Session Type: Mini Oral session

386MO - Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial.

Trastuzumab duocarmazine与医生选择疗法治疗既往接受过治疗的HER2阳性转移性乳腺癌：III期TULIP试验的最终结果。

Presentation Number: 386MO

Speakers: Philippe G. Aftimos (Anderlecht, Belgium)

Lecture Time: 09:35 - 09:40

Session Name: Mini oral session - Breast cancer, metastatic (ID 77)

Date: Sun, 22.10.2023

Session Type: Mini Oral session

33P - Visualizing Trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale

Presentation Number 33P.

在纳米水平上可视化德曲妥珠单抗对HER2阳性乳腺癌细胞的作用。

Speakers: Katia Cortese (Genova, Italy)

Onsite Poster display date: Sun, 22.10.2023

388P - Subgroup Analysis of Patients (pts) With HER2-Low Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) at Baseline From DESTINY-Breast04, a Randomized Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) vs Treatment of Physician’s Choice (TPC).

比较德曲妥珠单抗 (T-DXd) 与医生选择疗法 (TPC) 的随机III期研究——DESTINY-Breast04研究中基线伴脑转移 (BM) 的HER2低表达转移性乳腺癌 (mBC) 患者的亚组分析。

Presentation Number: 388P

Speakers: Junji Tsurutani (Shinagawa-ku, Japan)

Onsite Poster display date: Sat, 21.10.2023

389P - Efficacy and safety analyses by prior lines of chemotherapy from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC).

在HR+/HER2-转移性乳腺癌（mBC）患者（pts）中开展的对比戈沙妥珠单抗（SG）与医生选择疗法（TPC）的III期TROPiCS-02研究中，按既往化疗线数进行的疗效和安全性分析。

Presentation Number: 389P

Speakers: Javier Cortés (Madrid, Spain)

Onsite Poster display date: Sat, 21.10.202

397P - Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing, locally advanced or metastatic breast cancer: a single-arm phase II study.

重组人源化HER2靶向单抗MMAE偶联物RC48-ADC在HER2阳性或HER2低表达的局部晚期或转移性乳腺癌患者中疗效和安全性：单臂II期研究。

Presentation Number: 397P

Speakers: Fei Qu (Nanjing, China)

Onsite Poster display date: Sat, 21.10.2023

412P - Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.

戈沙妥珠单抗对比化疗治疗转移性乳腺癌的安全性荟萃分析。

Presentation Number 412P

Speakers Alessandro Rizzo (Bologna, Italy)

Onsite Poster display date: Sat, 21.10.2023

414P - Trastuzumab Deruxtecan for HER2-positive Breast Cancer Brain Metastasis: a Systematic Review and Meta-analysis.

德曲妥珠单抗治疗HER2阳性乳腺癌脑转移：系统综述与Meta分析。

Presentation Number: 414P

Speakers: Isabella F. Michelon (Pelotas, Brazil)

Onsite Poster display date: Sat, 21.10.2023

685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors.

HER2靶向抗体药物偶联物BL-M07D1用于局部晚期或转移性HER2表达乳腺癌和其他实体瘤患者的应用研究。

Presentation Number: 685P

Speakers: Erwei Song (Guangzhou, China)

Onsite Poster display date: Mon, 23.10.2023

LBA12 - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01.

对于经治的晚期/转移性（adv/met）非小细胞肺癌（NSCLC）进行Datopotamab deruxtecan（Dato-DXd）与多西他赛的对比研究：TROPION-Lung01随机III期研究的结果。

Presentation Number: LBA12

Speakers: Aaron E. Lisberg (Los Angeles, United States of America)

Lecture Time: 16:42 - 16:54

Session Name: Presidential 3 (ID 156)

Date: Mon, 23.10.2023

Session Type: Proffered Paper session

655O - Phase 1b Study of Cofetuzumab Pelidotin, an Anti-PTK7 Antibody-Drug Conjugate, in Patients with PTK7-Expressing Recurrent Non-Small Cell Lung Cancer (rNSCLC).

Cofetuzumab Pelidotin（一种靶向PTK7的抗体药物偶联物）在表达PTK7的复发性非小细胞肺癌 (rNSCLC) 患者中的1b期研究。

Presentation Number: 655O

Speakers: Byoung Chul Cho (Seoul, Korea, Republic of)

Lecture Time: 09:30 - 09:40

Session Name: Proffered Paper session - Developmental therapeutics (ID 80)

Date: Sun, 22.10.202

Session Type: Proffered Paper session

1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs).

TROPION-Lung05：Datopotamab deruxtecan(Dato-DXd) 治疗既往经治的携带可靶向基因组改变 (AGA) 的非小细胞肺癌 (NSCLC) 患者。

Presentation Number: 1314MO

Speakers: Luis Paz-Ares (Madrid, Spain)

Lecture Time: 09:30 - 09:35

Session Name: Mini oral session 1 - NSCLC, metastatic (ID 35)

Date: Sat, 21.10.2023

Session Type: Mini Oral session

1316MO - BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Non-Small Cell Lung Cancer: Updated results from first-in-human phase 1 study.

BL-B01D1 是一种首创的 EGFRxHER3 双特异性抗体药物偶联物，用于治疗非小细胞肺癌患者：首次人体 I 期研究的更新结果。

Presentation Number: 1316MO

Speakers: Li Zhang (Guangzhou, China)

Lecture Time: 09:40 - 09:45

Session Name: Mini oral session 1 - NSCLC, metastatic (ID 35)

Date: Sat, 21.10.2023

Session Type: Mini Oral session

1318MO - First-in-Human Study of ABBV-637, an EGFR-targeting BCL-XL–Inhibiting Antibody-Drug Conjugate Combined With Osimertinib (OSI) in Relapsed/Refractory, EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC).

ABBV-637（一种靶向EGFR的BCL-XL-抑制抗体药物偶联物）联合奥希替尼 (OSI) 治疗复发性/难治性 EGFR 突变非小细胞肺癌 (NSCLC) 的首次人体研究。

Presentation Number: 1318MO

Speakers: Julia K. Rotow (Boston, United States of America)

Lecture Time: 16:45 - 16:50

Session Name: Mini oral session 2 - NSCLC, metastatic (ID 114)

Date: Sun, 22.10.2023

Session Type: Mini Oral session

1319MO - Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01.

HER3-DXd对经治晚期EGFR突变非小细胞肺癌（NSCLC）患者的颅内疗效：来自HERTHENA-Lung01研究的结果。

Presentation Number: 1319MO

Speakers: Melissa L. Johnson (Nashville, United States of America)

Lecture Time: 17:05 - 17:10

Session Name: Mini oral session 2 - NSCLC, metastatic (ID 114)

Date: Sun, 22.10.2023

Session Type: Mini Oral session

1321MO - Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2 (ERBB2)-Mutant (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC) With and Without Brain Metastases (BMs): Pooled Analyses From DESTINY-Lung01 and DESTINY-Lung02.

德曲妥珠单抗（T-DXd）治疗伴或不伴脑转移（BMs）的HER2（ERBB2）突变（HER2m）转移性非小细胞肺癌（NSCLC）患者（pts）：DESTINY-Lung01研究和DESTINY-Lung02研究的汇总分析。

Presentation Number: 1321MO

Speakers: David Planchard (Villejuif, Cedex, France)

Lecture Time: 17:10 - 17:15

Session Name: Mini oral session 2 - NSCLC, metastatic (ID 114)

Date: Sun, 22.10.2023

Session Type: Mini Oral session

1990MO - Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase 2 TROPiCS-03 basket trial.

戈沙妥珠单抗（SG）用于广泛期小细胞肺癌（ES-SCLC）的二线（2L）治疗：II期TROPiCS-03篮字试验的初步结果。

Presentation Number: 1990MO

Speakers: Afshin Dowlati (Cleveland, United States of America)

Lecture Time: 14:55 - 15:00

Session Name: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies (ID 60)

Date: Sat, 21.10.2023

Session Type: Mini Oral session

151P - Baseline Circulating Tumor DNA (ctDNA) Biomarker Analysis of Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Non–Small Cell Lung Cancer (NSCLC) Treated With Trastuzumab Deruxtecan (T-DXd).

德曲妥珠单抗 (T-DXd）治疗人表皮生长因子受体 2 (HER2) 过表达转移性非小细胞肺癌 (NSCLC) 患者的基线循环肿瘤DNA (ctDNA) 生物标志物分析。

Presentation Number: 151P

Speakers: Egbert F. Smit (Leiden, Netherlands)

1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04).

Tusamitamab ravtansine联合ramucirumab方案用于CEACAM5高表达（CARMEN-LC04）的转移性NSq NSCLC 患者的2线及以后治疗的研究。

Presentation Number: 1411P

Speakers: Grace K. Dy (Buffalo, United States of America)

Onsite Poster display date: Mon, 23.10.2023

1419P - TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases.

TACSTD2（Trop-2）是治疗非小细胞肺癌脑转移患者的极具前景的抗体药物偶联物的靶点。

Presentation Number 1419P

Speakers Sara Hijazo-Pechero (Hospitalet de Llobregat, Spain)

Onsite Poster display date: Mon, 23.10.2023

1505TiP - TROPION-Lung07: A phase 3 trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression.

TROPION-Lung07研究：一项datopotamab deruxtecan（Dato-DXd）+帕博利珠单抗（pembro）联合或不联合铂类化疗（Pt-CT）作为PD-L1表达晚期/转移性（adv/met）非小细胞肺癌（NSCLC）一线（1L）治疗的III期试验。

Presentation Number: 1505TiP

Speakers: Isamu Okamoto (Fukuoka, Japan)

Onsite Poster display date: Mon, 23.10.2023

1507TiP - Phase 1b multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03.

德曲妥珠单抗(T-DXd) 和免疫疗法联合或不联合化疗用于HER2过表达(OE)晚期或转移性非鳞状非小细胞肺癌 (NSCLC) 患者 (pts) 的Ib期多中心研究：DESTINY-Lung03研究。

Presentation Number: 1507TiP

Speakers: David Planchard (Villejuif, Cedex, France)

Onsite Poster display date: Mon, 23.10.2023

LBA9 - innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin vs Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer.

innovaTV 301/ENGOT-cx12/GOGG-3057研究：一项对比Tisotumab Vedotin与研究者选择化疗方案针对2L或3L复发性或转移性宫颈癌的全球性、随机、开放标签III期研究。

Presentation Number: LBA9

Speakers: Ignace B. Vergote (Leuven, Belgium)

Lecture Time: 17:22 - 17:34

Session Name: Presidential 2 (ID 112)

Date: Sun, 22.10.2023

Session Type: Proffered Paper session

741MO - Luveltamab Tazevibulin (STRO-002), an anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate (ADC), Demonstrates Clinical Activity in Recurrent/Progressive Epithelial Endometrial Cancer (EEC): STRO-002-GM1 Phase 1 Dose Expansion.

抗叶酸受体α (FolRα) 抗体药物偶联物 (ADC) Luveltamab Tazevibulin (STRO-002) 在复发性/进展性上皮性子宫内膜癌 (EEC) 中显示出临床活性：STRO-002-GM1 I期剂量扩展研究。

Presentation Number: 741MO

Speakers: Bhavana Pothuri (New York, United States of America)

Lecture Time: 10:25 - 10:30

Session Name: Mini oral session - Gynaecological cancers (ID 90)

Date: Sun, 22.10.2023

Session Type: Mini Oral session

745MO - Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase 1 study.

Raludotatug deruxtecan(R-DXd；DS-6000) 单药治疗既往经治卵巢癌 (OVC) 患者：首次人体I期研究的亚组分析。

Presentation Number: 745MO

Speakers: Kathleen N. Moore (Oklahoma City, United States of America)

Lecture Time: 08:30 - 08:35

Session Name: Mini oral session - Gynaecological cancers (ID 90)

Date: Mon, 23.10.2023

Session Type: Mini Oral session

777P - Targeting Cadherin-6 in Epithelial Ovarian Cancer: Clinical Significance of its Expression and Efficacy of Raludotatug Deruxtecan（R-DXd）in Patient-Derived Cell Models.

靶向上皮性卵巢癌中Cadherin-6：Raludotatug Deruxtecan（R-DXd）在患者衍生细胞模型中的临床意义和疗效。

Presentation Number: 777P

Speakers: Daisuke Shintani (Saitama, Japan)

Onsite Poster display date: Sun, 22.10.2023

818TiP - REFRaME-O1/ENGOT-OV79/GOG-3086: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin versus Investigator’s Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer Expressing Folate Receptor alpha (FolRα).

REFRaME-O1/ENGOT-OV79/GOG-3086研究: 一项对比Luveltamab Tazevibulin与研究者选择化疗在叶酸受体α（FolRα）表达的复发性铂类耐药上皮性卵巢癌女性患者中疗效和安全性的II/III期开放标签研究。

Presentation Number: 818TiP

Speakers: R. Wendel Naumann (Concord, United States of America)

Onsite Poster display date: Sun, 22.10.202

859MO - Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase 2 TROPiCS-03 basket trial.

Sacituzumab govitecan(SG) 治疗复发性/难治性 (R/R) 晚期头颈部鳞状细胞癌 (HNSCC) 患者：II期TROPiCS-03篮子试验的结果。

Presentation Number: 859MO

Speakers: Loren Michel (New York, United States of America)

Lecture Time: 11:10 - 11:15

Session Name: Mini oral session - Head and neck cancer (ID 45)

Date: Sat, 21.10.2023

Session Type: Mini Oral session

860MO - MRG003, a novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic Nasopharyngeal Carcinoma.

MRG003，一种用于复发性/转移性鼻咽癌的新型EGFR靶向抗体药物偶联物 (ADC)。

Presentation Number: 860MO

Speakers: Fei Han (Guangzhou, China)

Lecture Time: 11:15 - 11:20

Session Name: Mini oral session - Head and neck cancer (ID 45)

Date: Sat, 21.10.2023

Session Type: Mini Oral session

939P - Efficacy and Safety of a Novel Anti-EGFR ADC MRG003 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck patients.

新型EGFR靶向ADC药物MRG003在复发性或转移性头颈部鳞状细胞癌患者中的疗效和安全性。

Presentation Number: 939P

Speakers: Liqiong Xue (Shanghai, China)

Onsite Poster display date: Sun, 22.10.2023

LBA6 - EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC).

EV-302/KEYNOTE-A39研究：Enfortumab Vedotin联合帕博利珠单抗（EV+P）与化疗（Chemo）治疗既往未经治疗的局部晚期转移性尿路上皮癌（la/mUC）的开放标签、随机III期研究。

Presentation Number: LBA6

Speakers: Thomas B. Powles (London, United Kingdom)

Lecture Time: 16:30 - 16:42

Session Name: Presidential 2 (ID 112)

Date: Sun, 22.10.2023

Session Type: Proffered Paper session

2360MO - The Double Antibody Drug conjugate (DAD) Phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ Second line therapy for metastatic urothelial carcinoma (mUC).

双抗体药物偶联物 (DAD)的I期试验：Sacituzumab govitecan(SG) + enfortumab vedotin(EV) 作为转移性尿路上皮癌 (mUC) 的≥2线治疗。

Presentation Number: 2360MO

Speakers: Bradley A. McGregor (Boston, United States of America)

Lecture Time: 10:15 - 10:20

Session Name: Proffered Paper session 1 - Genitourinary tumours, non-prostate (ID 27)

Date: Sun, 22.10.2023

Session Type: Mini Oral session

41P - Evaluation of ARX517, a next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models.

用于前列腺癌治疗的新一代PSMA靶向抗体药物偶联物ARX517在恩扎卢胺耐药和恩扎卢胺敏感的药理学模型以及毒理学模型中进行的临床前评估。

Presentation Number: 41P

Speakers: Shawn Zhang (La Jolla, United States of America)

Onsite Poster display date: Sun, 22.10.2023

1804P - APEX-01: First-in-human phase 1/2 study of ARX517, an anti-prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

APEX-01研究：前列腺特异性膜抗原（PSMA）靶向抗体药物偶联物（ADC）ARX517在转移性去势抵抗性前列腺癌（mCRPC）患者（pts）中的首次人体I/II期研究。

Presentation Number: 1804P

Speakers: John Shen (Los Angeles, United States of America)

Onsite Poster display date: Sun, 22.10.2023

1842TiP - Phase 2 Randomized Trial of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC; TAMARACK).

两种剂量水平的Vobramitamab Duocarmazine用于转移性去势抵抗性前列腺癌 (mCRPC; TAMARACK) 患者的II期随机试验。

Presentation Number: 1842TiP

Speakers: Johann S. De Bono (Sutton, United Kingdom)

Onsite Poster display date: Sun, 22.10.2023

LBA34 - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02 (DP-02) study.

德曲妥珠单抗（T-DXd）治疗经治的HER2表达实体瘤患者（pts）：DESTINY-PanTumor02（DP-02）研究的主要分析结果。

Presentation Number: LBA34

Speakers: Funda Meric-Bernstam (Houston, United States of America)

Lecture Time: 16:40 - 16:45

Session Name: Mini oral session - Developmental therapeutics (ID 268)

Date: Mon, 23.10.2023

Session Type：Mini Oral session

654O - Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the international phase 2 DESTINY-PanTumor01 (DPT-01) study.

德曲妥珠单抗（T-DXd）在携带特异性HER2激活突变（HER2m）实体瘤患者中的疗效和安全性：全球II期DESTINY-PanTumor01 (DPT-01)研究的主要结果。

Presentation Number: 654O

Speakers: Bob T. Li (New York, United States of America)

Lecture Time: 09:20 - 09:30

Session Name: Proffered Paper session - Developmental therapeutics (ID 80)

Date: Sun, 22.10.202

Session Type: Proffered Paper session

656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): results from the global phase 1 study.

针对HER2表达/突变晚期非乳腺癌实体瘤 (ST) 的HER2靶向ADC药物SHR-A1811：全球I期研究结果。

Presentation Number: 656MO

Speakers: Yiming Zhao (Guangzhou, China)

Lecture Time: 16:30 - 16:35

Session Name: Mini oral session - Developmental therapeutics (ID 268)

Date: Mon, 23.10.2023

Session Type: Mini Oral session

657MO - Recommended phase 2 dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors.

首次人体免疫刺激抗体偶联物（ISAC）BDC-1001在HER2表达晚期实体瘤患者中的推荐2期剂量选择（RP2D）和药效动力学（PD）数据。

Presentation Number: 657MO

Speakers: Bob T. Li (New York, United States of America)

Lecture Time: 16:35 - 16:40

Session Name: Mini oral session - Developmental therapeutics (ID 268)

Date: Mon, 23.10.2023

Session Type: Mini Oral session

658MO - Phase 1 study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors

Presentation Number: 658MO.

HER3靶向ADC药物SHR-A2009治疗晚期实体瘤的I期研究。

Speakers: Yi-Long Wu (Guangzhou, China)

Lecture Time: 16:40 - 16:45

Session Name: Mini oral session - Developmental therapeutics (ID 268)

Date: Mon, 23.10.2023

Session Type: Mini Oral session

659MO - Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting Nectin-4, in patients with advanced solid tumors.

Nectin-4靶向ADC药物9MW2821治疗晚期实体瘤的I/II期临床研究初步结果。

Presentation Number: 659MO

Speakers: Jian Zhang (Shanghai, China)

Lecture Time: 17:20 - 17:25

Session Name: Mini oral session - Developmental therapeutics (ID 268)

Date: Mon, 23.10.2023

Session Type: Mini Oral session

660MO - First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase 1 study (SGNB7H4V-001).

SGN-B7H4V（一种B7-H4靶向vedotin ADC）在晚期实体瘤患者中的首次人体研究：I期研究 (SGNB7H4V-001) 的初步结果。

Presentation Number: 660MO

Speakers: Cesar A. Perez (Fort Myers, United States of America)

Lecture Time: 17:25 - 17:30

Session Name: Mini oral session - Developmental therapeutics (ID 268)

Date: Mon, 23.10.2023

Session Type: Mini Oral session

148P - DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma.

针对HER2表达实体瘤患者开展的德曲妥珠单抗(T-DXd) DESTINY-PanTumor02研究：组织和血浆中HER2表达和基因扩增的生物标志物探索性分析。

Presentation Number: 148P

Speakers: Vicky Makker (New York City, United States of America)

Onsite Poster display date: Sat, 21.10.2023

375TiP - A phase 1, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors.

DS-1103a联合德曲妥珠单抗 (T-DXd) 用于晚期实体瘤患者的 I期、部分II期，首次人体多中心剂量递增和剂量扩增研究。

Presentation Number: 375TiP

Speakers: Ludimila Cavalcante (Atlanta, United States of America)

Onsite Poster display date: Sat, 21.10.2023

438P - Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors.

ZV0203（首创帕妥珠单抗ADC）针对HER2阳性晚期实体瘤患者的I期研究。

Presentation Number 438P

Speakers Fengjuan Lin (Shanghai, China)

Onsite Poster display date: Sat, 21.10.2023

689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) 1/2a study.

DB-1305（Trop-2靶向抗体药物偶联物ADC）在晚期实体瘤患者（pts）中的应用：I/IIa期研究的初步临床结果。

Presentation Number: 689P

Speakers: Omkar Marathe (Fountain Valley, United States of America)

Onsite Poster display date: Mon, 23.10.2023

690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: updated clinical and biomarker results from a phase 1/2 study.

Ifinatamab deruxtecan (I-DXd; DS-7300) 治疗晚期实体瘤患者：I/II期研究的最新临床数据和生物标志物结果。

Presentation Number: 690P

Speakers: Manish R Patel (Fort Myers, United States of America)

Onsite Poster display date: Mon, 23.10.2023

692P - First-in-Human Study of ELU001, a Targeted Nanoparticle Drug Conjugate, in Subjects with Folate Receptor α (FRα) Overexpressing Solid Tumors.

在叶酸受体α（FRα）过表达实体瘤患者中应用ELU001（一种纳米粒子靶向药物偶联物）的首次人体试验。

Presentation Number: 692P

Speakers: Wen wee Ma (Sandusky, United States of America)

Onsite Poster display date: Mon, 23.10.2023

2029TiP - Phase 1 study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors.

SEZ6靶向抗体药物偶联物ABBV-706单独或联合用于晚期实体瘤成人患者的I期研究。

Presentation Number: 2029TiP

Speakers: Sreenivasa Chandana (Grand Rapids, United States of America)

Onsite Poster display date: Sat, 21.10.2023

1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: options for new clinical opportunities.

黑色素瘤中抗体药物偶联物 (ADC) 和PD-L1的肿瘤相关抗原 (TAAs) 的转录组评估：新的临床机遇选择。

Presentation Number 1171P

Speakers Jorge Bartolome (Madrid, Spain)

Onsite Poster display date: Sun, 22.10.2023

1574P - Trastuzumab Deruxtecan versus Ramucirumab and Paclitaxel as second-line therapy for patients with HER2-positive gastric or gastro-esophageal junction adenocarcinoma: a propensity score matched comparison.

德曲妥珠单抗对比雷莫西尤单抗+紫杉醇用于HER2阳性胃癌或胃食管交界处腺癌患者的二线治疗：倾向评分匹配法比较研究。

Presentation Number: 1574P

Speakers: Rob H. Verhoeven (Utrecht, Netherlands)

Onsite Poster display date: Mon, 23.10.2023

71P - Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers.

用于治疗CD70表达肿瘤的新一代CD70靶向抗体药物偶联物ARX305的临床前特性研究。

Presentation Number 71P

Speakers Lillian Skidmore (La Jolla, United States of America)

Onsite Poster display date: Sun, 22.10.2023

683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer.

EGFR靶向ADC药物HLX42用于西妥昔单抗或TKI耐药肿瘤的临床前评估。

Presentation Number: 683P

Speakers: Yongqiang Shan (Shanghai, China)

Onsite Poster display date: Mon, 23.10.2023

693P - Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models.

PD-L1靶向ADC药物HLX43在多种PD-1/PD-L1难治/耐药模型中的临床前活性。

Presentation Number: 693P

Speakers: Yongqiang Shan (Shanghai, China)

Onsite Poster display date: Mon, 23.10.2023

756P - First-in-Human Phase 1 Study of a Novel Claudin 6 (CLDN6) targeted Antibody Drug Conjugate (ADC) TORL-1-23.

新型Claudin 6 (CLDN6) 靶向抗体药物偶联物 (ADC) TORL-1-23 的首次人体I期研究。

Presentation Number: 756P

Speakers: Gottfried E. Konecny (Los Angeles, United States of America)

Onsite Poster display date: Sun, 22.10.2023

1828P - ARX517, a next generation anti-PSMA antibody drug conjugate (ADC), demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase 1 clinical trial (APEX-01).

新一代PSMA靶向抗体药物偶联物（ADC）ARX517在ARX517 I期临床试验（APEX-01）中展现出显著的稳定性和药代动力学（PK）特征。

Presentation Number 1828P

Speakers Scott T. Tagawa (New York, United States of America)

Onsite Poster display date: Sun, 22.10.2023

2090P - Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.

德曲妥珠单抗相关恶心和呕吐在真实世界的应对方法。

Presentation Number: 2090P

Speakers: Luca Licata (Milan, Italy)

Onsite Poster display date: Sat, 21.10.2023

2155P - Outcomes With Trastuzumab Deruxtecan (T-DXd) Retreatment After Recovery From First Interstitial Lung Disease/Pneumonitis (ILD/p).

首次间质性肺病/肺炎（ILD/p）康复后德曲妥珠单抗（T-DXd）再治疗的效果。

Presentation Number: 2155P

Speakers: Hope S. Rugo (San Francisco, United States of America)

Onsite Poster display date: Sat, 21.10.202